Definium Therapeutics Inc. CEO Rob Barrow hailed a “profound change” in the treatment of major depressive disorder (MDD) as his firm rolled out positive top-line results from Emerge, the first randomized, double-blind, placebo-controlled phase III study evaluating a single dose of DT-120 (lysergide, otherwise known as LSD), given to adults as an orally disintegrating tablet 100 µg.